Population Pharmacokinetics of Telmisartan in Healthy Subjects and Hypertensive Patients PopPKs of Telmisartan in Healthy Subjects and Hypertensive Patients

• Published in: Clinical pharmacokinetics Vol. 64; no. 2; pp. 285 - 295
• Main Authors: Jeong, In Hwan, Ryu, Sooyoon, Han, Nayoung, Staatz, Christine E., Baek, In-hwan
• Format: Journal Article
• Language: English
• Published: Cham Springer International Publishing 01.02.2025
• Subjects: Internal Medicine; Medicine; Medicine & Public Health; Original Research Article; Pharmacology/Toxicology; Pharmacotherapy
• ISSN: 0312-5963; 1179-1926
• DOI: 10.1007/s40262-024-01471-3

Background and Objective Telmisartan exhibits significant pharmacokinetic (PK) variability, but it remains unclear whether its PK profile is altered in hypertensive patients. This study aimed to characterize telmisartan PKs by conducting a meta-analysis and developing a pooled population PK model based on data from healthy subjects and hypertensive patients. Methods Relevant literature was identified by a systematic approach. Eighteen studies were selected for analysis, which included 394 healthy subjects receiving single doses of telmisartan, 190 healthy subjects receiving repeated doses, along with 295 hypertensive patients receiving repeated doses. Pooled population PK analysis incorporated 20 mean concentration-time profiles from 14 studies. Meta-analyses were performed using OpenMeta-Analyst, and population PK modeling was performed using NONMEM ® . Results Repeated telmisartan doses increased peak plasma concentrations. However, other noncompartmental PK parameters remained consistent across healthy and hypertensive populations. Telmisartan PKs were best described using a two-compartment model with first-order absorption and elimination in pooled analysis. Typical PK parameter values for apparent clearance (CL/ F ), apparent central and peripheral volumes of distribution ( V 1 / F and V 2 / F ), absorption rate constant ( k a ), and absorption lag time were 18.3 L/h, 20.7 L, 360 L, 0.183 h −1 and 0.228 h, respectively. Interindividual variabilities in CL/ F , V 1 / F , and k a were 84%, 122%, and 106%, respectively. Covariate analysis revealed significantly lower CL/ F (63.7%) and V 1 / F (90.3%) values in hypertensive patients than healthy subjects. Conclusion These findings quantified the variability of telmisartan PK profile and highlighted the differences between healthy individuals and hypertensive patients, suggesting the need for optimized dosage strategies to improve therapeutic outcomes.